CORONA Remedies Limited vs Sun Pharmaceutical Industries Limited
A side-by-side comparison of CORONA Remedies Limited (CORONA) and Sun Pharmaceutical Industries Limited (SUNPHARMA) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.
On the numbers, Sun Pharmaceutical Industries Limited leads CORONA vs SUNPHARMA on 10 of 14 metrics. See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).
- Valuation04
- Profitability22
- Growth20
- Size & financial health04
Each axis shows this group's split of that metric, scaled so the leader sits at the edge. Relative to each other, not an absolute score.
Valuation
SUNPHARMA takes 4/4How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.
Profitability
EvenHow efficiently each company turns capital and sales into profit. Higher is better.
Growth
CORONA takes 2/2Three-year compounded growth. Faster-growing businesses can justify a higher valuation.
Size & financial health
SUNPHARMA takes 4/4Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.
- + ["Company has delivered good profit growth of 21.5% CAGR over last 5 years", "Company has a good return on equity (ROE) track record: 3 Years ROE 25.0%", "Company has been maintaining a healthy dividend payout of 33.0%", "Company has delivered good sales growth of 19.5% CAGR over last 5 years"]
- − ["Stock is trading at 16.41 times its book value"]
- + ["Company has delivered good profit growth of 38.3% CAGR over last 5 years", "Company has been maintaining a healthy dividend payout of 33.4%", "Company is almost debt free."]
- − ["Stock is trading at 5.05 times its book value"]
This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.